ARGX

Argen X (ARGX)

Argen X SE

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:EU:ARGX

1 2 3 4 5 6 7 8 9 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/26	05:30	GlobeNewswire Inc.	argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting	EU:ARGX	Argen X SE
2024/06/22	05:50	GlobeNewswire Inc.	argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy	EU:ARGX	Argen X SE
2024/06/17	14:00	GlobeNewswire Inc.	argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024	EU:ARGX	Argen X SE
2024/06/04	14:00	GlobeNewswire Inc.	argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference	EU:ARGX	Argen X SE
2024/05/09	14:00	GlobeNewswire Inc.	argenx Reports First Quarter 2024 Financial Results and Provides Business Update	EU:ARGX	Argen X SE
2024/05/08	06:30	GlobeNewswire Inc.	argenx announces results of Annual General Meeting of Shareholders	EU:ARGX	Argen X SE
2024/05/07	14:00	GlobeNewswire Inc.	argenx to Present at BofA Securities 2024 Health Care Conference	EU:ARGX	Argen X SE
2024/05/02	14:00	GlobeNewswire Inc.	argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024	EU:ARGX	Argen X SE
2024/04/16	14:00	GlobeNewswire Inc.	argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	EU:ARGX	Argen X SE
2024/03/27	15:00	GlobeNewswire Inc.	argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	EU:ARGX	Argen X SE
2024/03/27	05:00	GlobeNewswire Inc.	argenx Announces Annual General Meeting of Shareholders on May 7, 2024	EU:ARGX	Argen X SE
2024/03/26	15:00	GlobeNewswire Inc.	argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	EU:ARGX	Argen X SE
2024/03/08	06:01	GlobeNewswire Inc.	argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	EU:ARGX	Argen X SE
2024/02/29	15:00	GlobeNewswire Inc.	argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	EU:ARGX	Argen X SE
2024/02/26	15:00	GlobeNewswire Inc.	argenx to Present at Upcoming Investor Conferences	EU:ARGX	Argen X SE
2024/02/22	15:00	GlobeNewswire Inc.	argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024	EU:ARGX	Argen X SE
2024/02/20	15:00	GlobeNewswire Inc.	argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	EU:ARGX	Argen X SE
2024/01/18	15:00	GlobeNewswire Inc.	argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis	EU:ARGX	Argen X SE
2024/01/08	15:00	GlobeNewswire Inc.	argenx Highlights 2024 Strategic Priorities	EU:ARGX	Argen X SE
2024/01/02	15:00	GlobeNewswire Inc.	argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference	EU:ARGX	Argen X SE
2023/12/20	15:00	GlobeNewswire Inc.	argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus	EU:ARGX	Argen X SE
2023/11/28	15:00	GlobeNewswire Inc.	argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia	EU:ARGX	Argen X SE
2023/11/16	21:40	GlobeNewswire Inc.	argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis	EU:ARGX	Argen X SE
2023/11/01	15:00	GlobeNewswire Inc.	argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions	EU:ARGX	Argen X SE
2023/11/01	15:00	GlobeNewswire Inc.	argenx to Present at Upcoming Investor Conferences	EU:ARGX	Argen X SE
2023/10/31	15:00	GlobeNewswire Inc.	argenx Reports Third Quarter 2023 Financial Results and Provides Business Update	EU:ARGX	Argen X SE
2023/10/24	14:00	GlobeNewswire Inc.	argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023	EU:ARGX	Argen X SE
2023/09/21	14:00	GlobeNewswire Inc.	argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis	EU:ARGX	Argen X SE
2023/09/15	14:00	GlobeNewswire Inc.	argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis	EU:ARGX	Argen X SE
2023/08/30	14:00	GlobeNewswire Inc.	argenx to Present at Upcoming Investor Conferences	EU:ARGX	Argen X SE